NZ197475A - Antibacterial combinations based on sulfamerazine and 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidine - Google Patents
Antibacterial combinations based on sulfamerazine and 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidineInfo
- Publication number
- NZ197475A NZ197475A NZ197475A NZ19747581A NZ197475A NZ 197475 A NZ197475 A NZ 197475A NZ 197475 A NZ197475 A NZ 197475A NZ 19747581 A NZ19747581 A NZ 19747581A NZ 197475 A NZ197475 A NZ 197475A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sulfamerazine
- active substance
- accordance
- diamino
- pyrimidine
- Prior art date
Links
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 title claims description 10
- 229960002597 sulfamerazine Drugs 0.000 title claims description 10
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 6
- BFCRRLMMHNLSCP-UHFFFAOYSA-N brodimoprim Chemical compound COC1=C(Br)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 BFCRRLMMHNLSCP-UHFFFAOYSA-N 0.000 title claims description 4
- 239000013543 active substance Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 229940124530 sulfonamide Drugs 0.000 description 6
- 150000003456 sulfonamides Chemical class 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 4
- 229960005404 sulfamethoxazole Drugs 0.000 description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical class OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH491680 | 1980-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ197475A true NZ197475A (en) | 1984-05-31 |
Family
ID=4284769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ197475A NZ197475A (en) | 1980-06-26 | 1981-06-19 | Antibacterial combinations based on sulfamerazine and 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidine |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0043055A1 (enrdf_load_html_response) |
| JP (1) | JPS5732220A (enrdf_load_html_response) |
| AU (1) | AU7196881A (enrdf_load_html_response) |
| CU (1) | CU35465A (enrdf_load_html_response) |
| GR (1) | GR82351B (enrdf_load_html_response) |
| MC (1) | MC1385A1 (enrdf_load_html_response) |
| NZ (1) | NZ197475A (enrdf_load_html_response) |
| PH (1) | PH16745A (enrdf_load_html_response) |
| ZA (1) | ZA814160B (enrdf_load_html_response) |
| ZW (1) | ZW10681A1 (enrdf_load_html_response) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH651473A5 (de) * | 1982-07-29 | 1985-09-30 | Joachim Karl Prof Dr Seydel | Pharmazeutisches praeparat. |
| HU197986B (en) * | 1987-02-25 | 1989-07-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing veterinary preparation of synergic effect |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK136470B (da) * | 1973-11-08 | 1977-10-17 | Hoffmann La Roche | Analogifremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimidinderivater eller salte deraf. |
-
1981
- 1981-05-07 ZW ZW106/81A patent/ZW10681A1/xx unknown
- 1981-05-27 CU CU8135465A patent/CU35465A/es unknown
- 1981-06-17 JP JP9241681A patent/JPS5732220A/ja active Pending
- 1981-06-19 NZ NZ197475A patent/NZ197475A/en unknown
- 1981-06-19 AU AU71968/81A patent/AU7196881A/en not_active Abandoned
- 1981-06-19 ZA ZA814160A patent/ZA814160B/xx unknown
- 1981-06-22 EP EP81104751A patent/EP0043055A1/de not_active Ceased
- 1981-06-23 MC MC811523A patent/MC1385A1/xx unknown
- 1981-06-24 GR GR65324A patent/GR82351B/el unknown
- 1981-06-25 PH PH25815A patent/PH16745A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH16745A (en) | 1984-02-10 |
| EP0043055A1 (de) | 1982-01-06 |
| GR82351B (enrdf_load_html_response) | 1984-12-13 |
| ZW10681A1 (en) | 1982-02-24 |
| JPS5732220A (en) | 1982-02-20 |
| ZA814160B (en) | 1982-07-28 |
| MC1385A1 (fr) | 1982-04-27 |
| AU7196881A (en) | 1982-01-07 |
| CU35465A (en) | 1982-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| US3949089A (en) | Substituted guanidine compounds as antifibrillatory agents | |
| IL110689A0 (en) | Substituted aryloxyalkyl diamine derivatives, their preparation and pharmaceutical compositions containing them | |
| CA2450359A1 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| SE9901573D0 (sv) | New compounds | |
| MX2023014547A (es) | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). | |
| US20110144046A1 (en) | Anthelmintic compositions | |
| DE4130061A1 (de) | Furanderivate enthaltende pharmazeutische praeparate | |
| NZ197475A (en) | Antibacterial combinations based on sulfamerazine and 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidine | |
| NZ236055A (en) | Use of pyrimidine-substituted piperazine derivative in the treatment of depression | |
| WO2000066550A8 (en) | New compounds | |
| US5248669A (en) | Inhibition of anoxia or hypoxia-induced, endothelium-mediated vasospasm with avermectins | |
| DE69029814T2 (de) | Inhibitoren der dihydrofolatreduktase von pneumocystis carinii | |
| DE60307327T2 (de) | Verwendung von Pteridin-Derivaten für die Behandlung von erhöhtem intrakranialem Druck | |
| DE69506702T2 (de) | Verwendung einer naphtolsulfonsäure zur hemmung der retroviraler infektionen | |
| US3519712A (en) | Therapeutic compositions comprising n-methylglucamine and coumermycin or salts thereof | |
| KR100395607B1 (ko) | 버지니아마이신혼합물 | |
| US5886000A (en) | Anti-HIV agent | |
| US4871722A (en) | Synergistic veterinary composition and/or fodder premix and process for preparing same | |
| EP0009657B1 (de) | Mittel mit diuretischer Wirkung enthaltend 2,4-Diamino-5-(4-amino-3,5-dimethoxybenzyl)-pyrimidin und ein Kalium-ausschwemmendes Diuretikum und deren Herstellung | |
| US3639632A (en) | Antimicrobial compositions containing 1 1'-hexamethylenebis (5-(2 - ethylhexyl) biguanide) dihydrochloride and 4-chloro-2-hydroxyphenyl 24 - dichlorophenyl ether | |
| DE2455370C3 (de) | Antibakterielles Arzneimittel | |
| US4039667A (en) | Antibacterial compositions | |
| EP0626849A1 (en) | Brofaromine as an agent for treating post-traumatic stress | |
| US4146620A (en) | Antibacterial compositions |